Walgreens Chosen for Alzheimer's Trial Recruitment
Walgreens and Prothena partner to increase access and enrollment in Alzheimer’s disease clinical trial
Late-stage clinical biotechnology company Prothena has engaged Walgreens for its patient identification and recruitment of its ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. PRX012 has been granted Fast Track designation by the FDA.
Ramita Tandon, chief clinical trials officer, Walgreens said in a press release, “Through Walgreens trusted community pharmacy presence and daily interactions with millions of patients across America, we believe we can have a meaningful impact in helping Prothena with their clinical trial recruitment efforts. Our aim is to help build a more representative patient population for Alzheimer’s research, particularly among underserved and diverse communities, to create a better understanding of this disease.”
Using Walgreens pharmacy and patient-authorized clinical data, the company will identify and engage with potentially eligible patients and their caregivers to educate them on Prothena’s ASCENT-2 clinical trial. Walgreens will then invite interested patients or their caregivers to complete a pre-screen to determine eligibility for participation at one of Prothena’s clinical trial sites.
Prothena’s Phase I PRX012 single ascending dose (SAD) and multiple ascending dose (MAD) studies are ongoing with topline data expected year end 2023.
Reference: Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial. DEERFIELD, Ill. & DUBLIN--BUSINESS WIRE.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
